National Comprehensive Cancer Network

Members Only
NCCN Oncology Research Program (ORP)
NCCN Mirvetuximab Soravtansine-Preclinical Research Grant Opportunity – Submit by October 26, 2015
Study Proposal Submission-NCCN RMS
ORP Recent News
ORP Affiliate Research Consortium
ORP Scientific Publications
ORP for Industry
ORP Investigator Steering Committee
ORP Testimonials
Clinical Trials at NCCN Member Institutions
Find NCCN ORP Funded Clinical Trials at NCCN Member Institutions
ORP Grant History
Informed Consent Language Database
Points to Consider on the Best Practices for Biorepositories, Registries and Databases
NCCN Shared Resources (Members Only
ORP Disclosure Policy
Call for Abstracts: NCCN General Poster Session
NCCN Collaboration with the National Business Group on Health
NCCN Health Information Technology Licensees

NCCN Research & Business Resources

Find a clinical trial >

Profile

The Alvin J. Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine is an international leader in cancer treatment, research, prevention, education, and community outreach. It is the only cancer center in Missouri and within a 240-mile radius of St. Louis to hold the Comprehensive Cancer Center designation from the National Cancer Institute (NCI). Parent institutions Barnes-Jewish Hospital and Washington University School of Medicine also are nationally recognized, with U.S. News & World Report magazine consistently ranking both among the best in the country.

Siteman offers the expertise of more than 350 Washington University research scientists and physicians who provide care for about 8,000 newly diagnosed cancer patients each year. Advanced diagnostic and treatment services are available in a state-of-the-art outpatient facility on Siteman’s main campus at Barnes-Jewish Hospital in St. Louis and at two satellite facilities in surrounding counties. Patients have access to support services throughout their care, including psychosocial and nutritional counseling, educational programs, support groups, pet therapy, and art therapy.

Scientists and physicians affiliated with Siteman hold more than $165 million in cancer research and related training grants. This includes federally funded translational initiatives in nanotechnology, chemoprevention, gene therapy, proteomics, imaging, genomics, and leukemia and lymphoma. More than 30 multiproject or collaborative cancer grants are held by Siteman investigators.

State-of-the-art research facilities include Washington University's world-renowned Genome Center and a Good Manufacturing Practice laboratory for the production of cellular and biological products that is one of the largest facilities of its type at a U.S. academic medical center.

Patients have access to more than 250 therapeutic clinical trials, including studies initiated by Siteman investigators and collaborative efforts with other leading cancer centers. Accruals to therapeutic studies have increased to almost 1,200 patients a year. Washington University's Mallinckrodt Institute of Radiology was a founding member of the Radiation Therapy Oncology Group, and Siteman participates in a variety of other cooperative clinical research groups.

As a Comprehensive Cancer Center , Siteman is committed to community outreach, education, and screening. In 2009, the cancer center's outreach programs reached more than 50,000 individuals throughout the region. Siteman's Program for the Elimination of Cancer Disparities strives to reduce barriers to cancer education, care, and research for underserved groups.